Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04214652 · ClinicalTrials.gov registry record · Phase 3
Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris
A Phase 3 study, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 3
- Development phase
- 180
- Enrollment target
NCT04214652 is a Phase 3 study that has completed, run by Bausch Health Americas. The registered enrollment target is 180 participants.
The verdict
NCT04214652, a Phase 3 study, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 180 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, double-blind, vehicle-controlled, 12-week study designed to assess the safety, tolerability, and efficacy of IDP-126 Gel in comparison IDP-126 Vehicle Gel at Weeks 2, 4, 8, and 12.
Interventions
- DRUG IDP-126 Gel
- DRUG IDP-126 Vehicle Gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2020-01-27 |
| Est. Completion | 2021-03-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04214652
The ClinicalTrials.gov registry entry for NCT04214652 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which IDP-126 Gel is the first listed.
NCT04214652 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04214652 about?
NCT04214652 is a clinical study titled "Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris". This is a multicenter, randomized, double-blind, vehicle-controlled, 12-week study designed to assess the safety, tolerability, and efficacy of IDP-126 Gel in comparison IDP-126 Vehicle Gel at Weeks 2, 4, 8, and 12.
What is the current status of trial NCT04214652?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 180 participants. The study started on 2020-01-27. Estimated completion is 2021-03-18.
What interventions are being tested in trial NCT04214652?
The interventions under investigation include: IDP-126 Gel (DRUG), IDP-126 Vehicle Gel (DRUG).
Who is sponsoring clinical trial NCT04214652?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.